Roche Strengthens Cancer Vaccine R&D With $1B immatics Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Combining immatics’ tumor-associated peptide vaccines with Roche’s checkpoint inhibitors is expected to provide a promising approach to the development of novel combination immunotherapies.